Epigenetic Inactivation of in Colorectal Cancer

Overview

Journal Ann Surg Treat Res

Specialty General Surgery

Date 2018 Jan 16

PMID 29333422

Citations 8

Authors

Eung Jin Shin

Han Jo Kim

Myoung Won Son

Tae Sung Ahn

Hyun Yong Lee

Dae Ro Lim

Sang Byung Bae

Seob Jeon

Hyungjoo Kim

Dongjun Jeong

Moon Soo Lee

Dong-Sun Kim

Jeong Se Noh

Moo-Jun Baek

Affiliations

Soon will be listed here.

Abstract

Purpose: Emerging evidence indicates that runt-related transcription factor 3 () is an important tumor suppressor gene in several cancer types, including colorectal cancer (CRC). However, the clinical significance of RUNX3 inactivation in CRC remains unclear. The aim of this study was to examine the correlation between clinicopathologic factors and RUNX3 hypermethylation/expression in CRC.

Methods: Sixty-two CRC patients who were treated at the Soonchunhyang University College of Medicine were recruited in this study. The hypermethylation of CpG islands in the RUNX3 promoter and the expression of RUNX3 mRNA were identified by methylation-specific polymerase chain reaction (PCR) and reverse transcriptase-PCR, respectively. The expression of RUNX3 was determined by immunohistochemical staining.

Results: Of the 62 CRC tissue samples, 20 (32.3%) presented hypermethylated RUNX3 promoters. Aberrant RUNX3 hypermethylation was found to be associated with vascular (P = 0.006) and lymphatic (P = 0.002) invasion. Hypermethylation of RUNX3 was associated with poor survival outcomes (P = 0.038). However, expression of RUNX3 was not a prognostic factor (P = 0.363).

Conclusion: Hypermethylation of RUNX3 may be a predictor of a poor prognosis in CRC.

Citing Articles

Ubiquitylation of RUNX3 by RNA-binding ubiquitin ligase MEX3C promotes tumorigenesis in lung adenocarcinoma.

He Z, Zhang H, Xiao H, Zhang X, Xu H, Sun R J Transl Med. 2024; 22(1):216.

PMID: 38424632 PMC: 10905843. DOI: 10.1186/s12967-023-04700-8.

The Role of CPNE7 (Copine-7) in Colorectal Cancer Prognosis and Metastasis.

Kong H, Kang D, Ahn T, Kim K, Kim T, Lee S Int J Mol Sci. 2023; 24(23).

PMID: 38069026 PMC: 10706690. DOI: 10.3390/ijms242316704.

High Expression of IRS-1, RUNX3 and SMAD4 Are Positive Prognostic Factors in Stage I-III Colon Cancer.

Selven H, Rasmussen Busund L, Andersen S, Pedersen M, Lombardi A, Kilvaer T Cancers (Basel). 2023; 15(5).

PMID: 36900240 PMC: 10000923. DOI: 10.3390/cancers15051448.

RUNX3-regulated circRNA METTL3 inhibits colorectal cancer proliferation and metastasis via miR-107/PER3 axis.

Zhang F, Su T, Xiao M Cell Death Dis. 2022; 13(6):550.

PMID: 35710754 PMC: 9203801. DOI: 10.1038/s41419-022-04750-8.

RUNX3/H3K27me3 Co-Expression Defines a Better Prognosis in Surgically Resected Stage I and Postoperative Chemotherapy-Naive Non-Small-Cell Lung Cancer.

Chen X, Deng Y, Huang C, Shi Y, Lu J, Weng G J Oncol. 2022; 2022:5752263.

PMID: 35368900 PMC: 8970863. DOI: 10.1155/2022/5752263.

References

Li Q, Kim H, Kim W, Choi J, Lee Y, Kim H . Transcriptional silencing of the RUNX3 gene by CpG hypermethylation is associated with lung cancer. Biochem Biophys Res Commun. 2004; 314(1):223-8. DOI: 10.1016/j.bbrc.2003.12.079. View

Xiao W, Liu W . Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma. World J Gastroenterol. 2004; 10(3):376-80. PMC: 4724901. DOI: 10.3748/wjg.v10.i3.376. View

Bae S, Choi J . Tumor suppressor activity of RUNX3. Oncogene. 2004; 23(24):4336-40. DOI: 10.1038/sj.onc.1207286. View

Ogino S, Meyerhardt J, Kawasaki T, Clark J, Ryan D, Kulke M . CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007; 450(5):529-37. DOI: 10.1007/s00428-007-0398-3. View

Fukushige S, Horii A . DNA methylation in cancer: a gene silencing mechanism and the clinical potential of its biomarkers. Tohoku J Exp Med. 2013; 229(3):173-85. DOI: 10.1620/tjem.229.173. View

Park W, Cho Y, Kim C, Song J, Lee Y, Kim S . Hypermethylation of the RUNX3 gene in hepatocellular carcinoma. Exp Mol Med. 2005; 37(4):276-81. DOI: 10.1038/emm.2005.37. View

Soong R, Shah N, Peh B, Chong P, Ng S, Zeps N . The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome. Br J Cancer. 2009; 100(5):676-9. PMC: 2653772. DOI: 10.1038/sj.bjc.6604899. View

Torquati A, ORear L, Longobardi L, Spagnoli A, Richards W, Beauchamp R . RUNX3 inhibits cell proliferation and induces apoptosis by reinstating transforming growth factor beta responsiveness in esophageal adenocarcinoma cells. Surgery. 2004; 136(2):310-6. DOI: 10.1016/j.surg.2004.05.005. View

Nakase Y, Sakakura C, Miyagawa K, Kin S, Fukuda K, Yanagisawa A . Frequent loss of RUNX3 gene expression in remnant stomach cancer and adjacent mucosa with special reference to topography. Br J Cancer. 2005; 92(3):562-9. PMC: 2362072. DOI: 10.1038/sj.bjc.6602372. View

10.

Goel A, Arnold C, Tassone P, Chang D, Niedzwiecki D, Dowell J . Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer. 2004; 112(5):754-9. DOI: 10.1002/ijc.20472. View

11.

Oshimo Y, Oue N, Mitani Y, Nakayama H, Kitadai Y, Yoshida K . Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma. Pathobiology. 2004; 71(3):137-43. DOI: 10.1159/000076468. View

12.

Nishio M, Sakakura C, Nagata T, Komiyama S, Miyashita A, Hamada T . RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker. Anticancer Res. 2010; 30(7):2673-82. View

13.

Ozaki T, Nakagawara A, Nagase H . RUNX Family Participates in the Regulation of p53-Dependent DNA Damage Response. Int J Genomics. 2013; 2013:271347. PMC: 3775453. DOI: 10.1155/2013/271347. View

14.

Mu W, Wang J, Niu Q, Shi N, Lian H . Clinical significance and association of RUNX3 hypermethylation frequency with colorectal cancer: a meta-analysis. Onco Targets Ther. 2014; 7:1237-45. PMC: 4105273. DOI: 10.2147/OTT.S62103. View

15.

Chi X, Yang J, Lee K, Ito K, Sakakura C, Li Q . RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol. 2005; 25(18):8097-107. PMC: 1234316. DOI: 10.1128/MCB.25.18.8097-8107.2005. View

16.

Lao V, Grady W . Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011; 8(12):686-700. PMC: 3391545. DOI: 10.1038/nrgastro.2011.173. View

17.

Levanon D, Brenner O, Otto F, Groner Y . Runx3 knockouts and stomach cancer. EMBO Rep. 2003; 4(6):560-4. PMC: 1319207. DOI: 10.1038/sj.embor.embor868. View

18.

Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29. DOI: 10.3322/caac.21208. View

19.

Ku J, Kang S, Shin Y, Kang H, Hong S, Kim I . Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene. 2004; 23(40):6736-42. DOI: 10.1038/sj.onc.1207731. View

20.

Li Q, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi X . Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002; 109(1):113-24. DOI: 10.1016/s0092-8674(02)00690-6. View